Written by Katherine Kramer, DVM, DAVBP (Canine & Feline Practice)
A 2019 survey among Canadian pet owners found that people who had tried hemp products on their pets did so for a variety of reasons. The main issues were to reduce pain & inflammation, anxiety, vomiting and to aid with sleep. Most veterinarians who are interested in veterinary cannabinoid medicine will agree that these are all common indications for the use of cannabis and will, most likely, add cancer and seizures to the list as well.
But what about cannabis for skin conditions? Records point to the ancient use of topical cannabis for wound healing, rashes and hair loss yet most of us today aren’t aware of these benefits. Investigating the role of cannabinoids in dermatology has been a growing field just over the last decade as scientists try to answer these questions: How does the endocannabinoid system (ECS) affect the largest mammalian organ and how this knowledge could translate into novel therapies for dermatologic disease?
Recent research has indicated that the ECS has a major role in the general skin homeostasis, epidermal permeability, hair growth, inflammation, pain, wound healing and skin tumors. Studies have demonstrated the presence of all the components of the ECS in the skin of multiple species, including the dog, cat and horse. These components, which include the endocannabinoids (primarily AEA and 2-AG), the receptors (Cb1, CB2, TRPV1, PPAR) and the necessary enzymes (such as FAAH and MAGL), have been found in keratinocytes, sebocytes, mast cells and adnexal skin tissues.
Particularly interesting are the findings of the interactions between mast cells, the ECS and N-acylethanolamines. Mast cells, of course, are multifunctional cells that play a huge role in the skin’s neuroimmune response in inflammatory and allergic reactions. They have been shown to metabolize endocannabinoids and express different types of cannabinoid receptors. N-acylethanolamines are a class of fatty acid amides that includes the endocannabinoid anandamide (AEA). This class also includes N-palmitoylethanolamine (PEA) which appears to be an ‘endocannabinoid-like mediator’. PEA has been shown to down-regulate mast cells and reduce mast cell degranulation in both canine and feline models. PEA also has the ability to increase the levels of 2-AG in keratinocytes and enhance the affinity of 2-AG for TRPV1 thus decreasing inflammation.
The therapeutic implications of all of these studies suggest that veterinary cannabinoid medicine may assist with dermatologic diseases involving inflammation and pruritus, hypersensitivity and wound healing. As usual, many more studies are needed to assess specific dermatologic indications and therapeutic dosages but the use of cannabinoids and endocannabinoid mediators appears to be extremely promising. The role of the ECS in dermatology definitely appears to be more than ‘skin deep’.
Abramo F, Campora L, Albanese F, et. al. Increased levels of palmitoylethanolamide and other bioactive lipid mediators and enhanced local mast cell proliferation in canine atopic dermatitis. BMC Vet Res, 2014; 10, 21.
Abramo F, Lazzarini G, Pirone A, et. al. Ultramicronized palmitoylethanolamide counteracts the effects of compound 48/80 in a canine skin organ culture model. Vet Dermatol, 2017; 28, 456-e104.
Barbero R, Vercelli C, Cuniberti B, et. al. Journal of Veterinary Pharmacology and Therapeutics, 2018; 41, 795-804.
Biro T, Toth BI, Hasko G, et. al. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol Sci, 2009; 30, 411-20.
Campora L, Miragliotta V, Ricci E, et. al. Cannabinoid receptor type 1 and 2 expression in the skin of healthy dogs and dogs with atopic dermatitis. Am J Vet Res, 2012; 73, 988-95.
Cerrato S, Brazis P, Della Valle MF, et. al. Effects of palmitoylethanolamide on the cutaneous allergic inflammatory response in Ascaris hypersensitive Beagle dogs. Vet J, 2012; 191, 377-82.
Cerrato S, Brazis P, Della Valle MF, et. al. Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFalpha release from canine skin mast cells. Vet Immunol Immunopathol, 2010; 133, 9-15.
De Filippis D, D’amico A, Iuvone T. Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation. J Neuroendocrinol, 2008; 20 Suppl 1, 20-5.
De Filippis D, Negro L, Vaia M, et. al. New insights in mast cell modulation by palmitoylethanolamide. CNS Neurol Disord Drug Targets, 2013; 12, 78-83.
Demora F, Garcia A, Puigdemont A, et. al. Skin mast cell releasability in dogs with atopic dermatitis. Inflammation Research, 1996: 45, 424-427.
Kogan L, Hellyer P, Silcox S, et al. Canadian dog owners’ use and perceptions of cannabis products. Can Vet J. 2019 Jul; 60(7): 749.755.
Marsella R, Joyce J, Nicklin C, et. al. Evaluation of the effects of Palmitoylethanolamide on clinical signs in house dust mite allergic high IgE Beagle dogs using a randomized, double blinded, placebo controlled design. Vet Dermatol, 2005; 1.
Mercati F, Dall’aglio C. Pascucci L, et. al. Identification of cannabinoid type 1 receptor in dog hair follicles. Acta Histochem, 2012; 114, 68-71.
Miragliotta V, Ricci PL, Albanese F, et. al. Cannabinoid receptor types 1 and 2 and peroxisome proliferator-activated receptor-alpha: distribution in the skin of clinically healthy cats and cats with hypersensitivity dermatitis. Vet Dermatol 2018.
Petrosino S, Cristino L, Karsak M, et. al. Protective role of palmitoylethanolamide in contact allergic dermatitis. Allergy, 2010; 65, 698-711.
Petrosino S, Schiano Moriello A, Cerrato A, et. al. The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at TRPV1 cation channels. Br J Pharmacol, 2016; 173, 1154-62.